Clinical Trials
31 trialsNCT04742101 2026-05-18
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Phase 1/2 Completed
NCT02993523 2026-05-15
Viale-a
AbbVie
Phase 3 Completed
NCT04687761 2026-05-13
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
PETHEMA Foundation
Phase 1/2 Completed
NCT05155709 2026-05-07
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis
Phase 1 Completed
NCT05829226 2026-05-06
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
Phase 1 Completed
NCT03466294 2026-04-09
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
University of Colorado, Denver
Phase 2 Completed
NCT04102020 2026-04-08
VIALE-M
AbbVie
Phase 3 Completed
NCT02816021 2026-04-06
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT01787487 2026-03-31
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT06565975 2026-02-12
RELION
Bristol-Myers Squibb
Completed
NCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03264404 2026-01-27
Azacitidine and Pembrolizumab in Pancreatic Cancer
Columbia University
Phase 2 Completed
NCT04139434 2026-01-23
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
Phase 1 Completed
NCT01869114 2025-12-10
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT05065866 2025-12-04
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02512172 2025-12-03
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03268954 2025-10-29
PANTHER
Takeda
Phase 3 Completed
NCT04266795 2025-10-21
PEVENAZA
Takeda
Phase 2 Completed
NCT04257448 2025-09-30
SEPION
GWT-TUD GmbH
Phase 1/2 Completed
NCT06326697 2025-09-26
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
Hikma Pharmaceuticals LLC
Phase 1 Completed
NCT05471700 2025-09-23
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
Zhujiang Hospital
Phase NA Completed
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT02752035 2025-09-12
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Astellas Pharma Inc
Phase 3 Completed
NCT02546986 2025-08-08
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT02269280 2025-08-07
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05662956 2025-07-15
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Hematology department of the 920th hospital
Phase 2 Completed
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT02719574 2025-06-26
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed